Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results
Aim. To assess effectiveness and safety of a selective beta-blocker bisoprolol in patients with chronic heart failure (CHF) and Type 2 diabetes mellitus (DM-2).Material and methods. In total, 81 patients with mild to moderate CHF, NYHA Functional Class (FC) II-III, left ventricular ejection fraction...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1552 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689364391526400 |
|---|---|
| author | Yu. V. Lapina A. A. Petrukhina O. Yu. Narusov V. Yu. Mareev M. G. Bolotina M. V. Shestakova V. P. Masenko G. N. Litonova N. A. Baklanova Yu. N. Belenkov |
| author_facet | Yu. V. Lapina A. A. Petrukhina O. Yu. Narusov V. Yu. Mareev M. G. Bolotina M. V. Shestakova V. P. Masenko G. N. Litonova N. A. Baklanova Yu. N. Belenkov |
| author_sort | Yu. V. Lapina |
| collection | DOAJ |
| description | Aim. To assess effectiveness and safety of a selective beta-blocker bisoprolol in patients with chronic heart failure (CHF) and Type 2 diabetes mellitus (DM-2).Material and methods. In total, 81 patients with mild to moderate CHF, NYHA Functional Class (FC) II-III, left ventricular ejection fraction (FV EF) <45 %, and DM-2 were examined. Bisoprolol group included 49 individuals (60 %), control group - 15 (18 %). Total length of therapy and follow-up was 12 months. Control examination was performed at baseline, after 6 months of the treatment, and at the end of the study. The examination included clinico-functional assessment of general status, renal function, neuro-hormonal profile, circadian heart rate variability, and carbohydrate metabolism (glycated hemoglobin level, standard breakfast test with fasting and 2- hour postprandial measurements of plasma glucose, insulin and C-peptide levels).Results. Bisoprolol substantially improved CHF FC, physical stress tolerability and LV EF, reducing heart rate and LV end-systolic volume, comparing to controls. Bisoprolol therapy did not affect DM-2 clinical course and did not result in insulin resistance progression or a need for more aggressive glucose-lowering therapy even among patients with clinically manifested CHF.Conclusion. Due to its demonstrated effectiveness and safety, bisoprolol could be recommended as a part of complex therapy in CHF and DM-2 patients. |
| format | Article |
| id | doaj-art-9520fa61d6d040c1bc518dc7c3539d24 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2008-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-9520fa61d6d040c1bc518dc7c3539d242025-08-20T03:21:39Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-08-017445531269Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study resultsYu. V. Lapina0A. A. Petrukhina1O. Yu. Narusov2V. Yu. Mareev3M. G. Bolotina4M. V. Shestakova5V. P. Masenko6G. N. Litonova7N. A. Baklanova8Yu. N. Belenkov9A.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesEndocrinology Research Center, Federal Agency on High Medical Technologies. MoscowA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesA.L. Myasnikov Research Institute of Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical TechnologiesAim. To assess effectiveness and safety of a selective beta-blocker bisoprolol in patients with chronic heart failure (CHF) and Type 2 diabetes mellitus (DM-2).Material and methods. In total, 81 patients with mild to moderate CHF, NYHA Functional Class (FC) II-III, left ventricular ejection fraction (FV EF) <45 %, and DM-2 were examined. Bisoprolol group included 49 individuals (60 %), control group - 15 (18 %). Total length of therapy and follow-up was 12 months. Control examination was performed at baseline, after 6 months of the treatment, and at the end of the study. The examination included clinico-functional assessment of general status, renal function, neuro-hormonal profile, circadian heart rate variability, and carbohydrate metabolism (glycated hemoglobin level, standard breakfast test with fasting and 2- hour postprandial measurements of plasma glucose, insulin and C-peptide levels).Results. Bisoprolol substantially improved CHF FC, physical stress tolerability and LV EF, reducing heart rate and LV end-systolic volume, comparing to controls. Bisoprolol therapy did not affect DM-2 clinical course and did not result in insulin resistance progression or a need for more aggressive glucose-lowering therapy even among patients with clinically manifested CHF.Conclusion. Due to its demonstrated effectiveness and safety, bisoprolol could be recommended as a part of complex therapy in CHF and DM-2 patients.https://cardiovascular.elpub.ru/jour/article/view/1552chronic heart failuretype 2 diabetes mellitusbisoprolol |
| spellingShingle | Yu. V. Lapina A. A. Petrukhina O. Yu. Narusov V. Yu. Mareev M. G. Bolotina M. V. Shestakova V. P. Masenko G. N. Litonova N. A. Baklanova Yu. N. Belenkov Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results Кардиоваскулярная терапия и профилактика chronic heart failure type 2 diabetes mellitus bisoprolol |
| title | Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results |
| title_full | Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results |
| title_fullStr | Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results |
| title_full_unstemmed | Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results |
| title_short | Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results |
| title_sort | selective beta blocker bisoprolol effectiveness and safety in complex treatment of patients with chronic heart failure and type 2 diabetes mellitus rambo dm chf study results |
| topic | chronic heart failure type 2 diabetes mellitus bisoprolol |
| url | https://cardiovascular.elpub.ru/jour/article/view/1552 |
| work_keys_str_mv | AT yuvlapina selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT aapetrukhina selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT oyunarusov selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT vyumareev selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT mgbolotina selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT mvshestakova selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT vpmasenko selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT gnlitonova selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT nabaklanova selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults AT yunbelenkov selectivebetablockerbisoprololeffectivenessandsafetyincomplextreatmentofpatientswithchronicheartfailureandtype2diabetesmellitusrambodmchfstudyresults |